Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: A systematic review

► Genetic polymorphisms are potential biomarkers in the treatment of gynecological malignancies. ► Associations between treatment outcome and polymorphisms in ERCC1, VEGF and MDR warrant further study. ► Validation of genetic biomarkers in clinical trials and adherence to REMARK guidelines is crucial to move the field forward.